Recent studies have identified that the activation of P53 inhibits the expression of SIRT1, resulting in increased p65 acetylation and nuclear factor (NF)-κB activation in the pathogenesis of CKD induced by repeated low-dose cisplatin treatment. The gene discussed is TP53; the disease is chronic kidney disease.